BE2013C045I2 - - Google Patents

Download PDF

Info

Publication number: BE2013C045I2
Authority: BE; Belgium
Prior art keywords: protein; large aggregates; conjugates; essentially; uricase
Prior art date: 2000-02-10

Application number

BE2013C045C

Other languages

English (en)

French (fr)

Original Assignee

Mountain View Pharmaceuticals Inc

Univ Duke

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-10

Filing date

2013-07-03

Publication date

2020-06-24

2013-07-03 Application filed by Mountain View Pharmaceuticals Inc, Univ Duke filed Critical Mountain View Pharmaceuticals Inc

2020-06-24 Publication of BE2013C045I2 publication Critical patent/BE2013C045I2/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BE2013C045C 2000-02-10 2013-07-03 BE2013C045I2 (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/501,730 US6783965B1 (en)	2000-02-10	2000-02-10	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PCT/US2001/040069 WO2001059078A2 (en)	2000-02-10	2001-02-07	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP01923265A EP1254237B1 (en)	2000-02-10	2001-02-07	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Publications (1)

Publication Number	Publication Date
BE2013C045I2 true BE2013C045I2 (zh)	2020-06-24

Family

ID=23994789

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2013C045C BE2013C045I2 (zh)	2000-02-10	2013-07-03

Country Status (28)

Country	Link
US (3)	US6783965B1 (zh)
EP (3)	EP2305819B1 (zh)
JP (2)	JP5165826B2 (zh)
KR (3)	KR20070092329A (zh)
CN (2)	CN101735991B (zh)
AT (1)	ATE463576T1 (zh)
AU (3)	AU2001249975B2 (zh)
BE (1)	BE2013C045I2 (zh)
BR (1)	BRPI0108386B8 (zh)
CA (1)	CA2398679C (zh)
CY (3)	CY1110142T1 (zh)
CZ (1)	CZ304864B6 (zh)
DE (1)	DE60141742D1 (zh)
DK (3)	DK2196538T3 (zh)
ES (2)	ES2524153T3 (zh)
FR (1)	FR13C0036I2 (zh)
HK (4)	HK1056742A1 (zh)
HU (1)	HU227127B1 (zh)
IL (3)	IL151065A0 (zh)
LU (1)	LU92237I2 (zh)
MX (1)	MXPA02007545A (zh)
NZ (1)	NZ520434A (zh)
PL (1)	PL208064B1 (zh)
PT (2)	PT2305819E (zh)
RU (3)	RU2281954C2 (zh)
TW (2)	TWI322184B (zh)
WO (1)	WO2001059078A2 (zh)
ZA (1)	ZA200207206B (zh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CN1896231B (zh)	1998-08-06	2012-09-05	山景药品公司	分离四聚体尿酸氧化酶的方法
IL141221A0 (en)	1998-08-06	2002-03-10	Univ Duke	Urate oxidase
US20060188971A1 (en) *	1998-08-06	2006-08-24	Duke University	Urate oxidase
US6783965B1 (en)	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
IL141220A0 (en) *	1998-08-06	2002-03-10	Mountain View Pharmaceuticals	Conjugates of peg-urate oxidase and use thereof
ATE414711T1 (de)	2001-06-28	2008-12-15	Mountain View Pharmaceuticals	Polymerstabilisierte proteinasen
US6913915B2 (en) *	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
DK2311432T3 (en) *	2002-06-07	2015-02-02	Dyax Corp	Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
US8129330B2 (en) *	2002-09-30	2012-03-06	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en)	2002-09-30	2004-04-01	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
NZ541124A (en) *	2002-12-26	2008-08-29	Mountain View Pharmaceuticals	Polymer conjugates of interferon-beta with enhanced biological potency
EP1625156B1 (en) *	2003-05-12	2012-09-19	Affymax, Inc.	Peptides that bind to the erythropoietin receptor
AU2004238364A1 (en)	2003-05-12	2004-11-25	Affymax, Inc.	Spacer moiety for poly(ethylene glycol) -modified peptides
CA2525464A1 (en) *	2003-05-12	2004-11-25	Qun Yin	Novel poly(ethylene glycol) modified compounds and uses thereof
ES2447423T3 (es) *	2003-08-29	2014-03-12	Dyax Corp.	Inhibidores de proteasa poli-pegilados
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20090005292A1 (en) *	2004-11-11	2009-01-01	Affymax, Inc.	Novel Peptides that Bind to the Erythropoietin Receptor
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
EP2279756A2 (en) *	2005-04-05	2011-02-02	Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A.	Method for shielding functional sites or epitopes on proteins
JP2008535500A (ja)	2005-04-11	2008-09-04	サビエントファーマセウティカルズインク．	変異型尿酸オキシダーゼおよびその利用
US20080159976A1 (en) *	2005-04-11	2008-07-03	Jacob Hartman	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2006110761A2 (en)	2005-04-11	2006-10-19	Savient Pharmaceuticals, Inc.	A variant form of urate oxidase and use thereof
US8148123B2 (en) *	2005-04-11	2012-04-03	Savient Pharmaceuticals, Inc.	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
JP2008545665A (ja) *	2005-05-23	2008-12-18	ユニベルシテドゥジュネーブ	高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) *	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
EP2013225B1 (en) *	2006-04-12	2014-12-17	Crealta Pharmaceuticals LLC	Purification of proteins with cationic surfactant
AU2008289005A1 (en) *	2007-08-21	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
CA2744235A1 (en)	2009-01-06	2010-07-15	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
SG176897A1 (en)	2009-06-25	2012-01-30	Savient Pharmaceuticals Inc	Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
LT3459564T (lt)	2010-01-06	2022-03-10	Takeda Pharmaceutical Company Limited	Plazmos kalikreiną surišantys baltymai
US8940861B2 (en)	2010-04-08	2015-01-27	Georgia Tech Research Corporation	Variants of ancestral uricases and uses thereof
BR112013017080A8 (pt)	2011-01-06	2023-05-09	Dyax Corp	Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
CN102827073A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
WO2014197806A2 (en)	2013-06-07	2014-12-11	Allena Pharmaceuticals, Inc.	Compositions, methods, and devices for dialysis
AU2014287121B2 (en)	2013-07-11	2018-11-15	Agios Pharmaceuticals, Inc.	2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9579324B2 (en)	2013-07-11	2017-02-28	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
WO2015003360A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
WO2015003355A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
US20150031627A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
US9968595B2 (en)	2014-03-14	2018-05-15	Agios Pharmaceuticals, Inc.	Pharmaceutical compositions of therapeutically active compounds
EP3122782A4 (en)	2014-03-27	2017-09-13	Dyax Corp.	Compositions and methods for treatment of diabetic macular edema
EP3294322A4 (en)	2015-05-15	2018-12-12	Medimmune, LLC	Improved uricase sequences and methods of treatment
ES2897959T3 (es)	2015-10-15	2022-03-03	Servier Lab	Terapia de combinación para tratar neoplasias malignas
AU2016338552B2 (en)	2015-10-15	2022-04-28	Les Laboratoires Servier	Combination therapy for treating malignancies
KR20180094028A (ko)	2015-12-11	2018-08-22	다이액스 코포레이션	혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
JP2019535819A (ja)	2016-11-11	2019-12-12	ホライゾンファーマリューマトロジーリミテッドライアビリティカンパニーＨｏｒｉｚｏｎＰｈａｒｍａＲｈｅｕｍａｔｏｌｏｇｙＬｌｃ	プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用
CA3069197A1 (en)	2017-07-07	2019-01-10	Allena Pharmaceuticals, Inc.	Recombinant uricase enzyme
US20190309269A1 (en)	2018-03-20	2019-10-10	Rubius Therapeutics, Inc.	Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
CN109055260B (zh) *	2018-08-08	2021-11-09	淮海工学院	弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
CN114181917B (zh) *	2022-02-14	2022-06-03	潍坊华卓生物科技有限公司	一种改造尿酸酶、基因序列、制备方法及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE279486C (zh)
US3616231A (en)	1968-11-14	1971-10-26	Boehringer Mannheim Gmbh	Process for the production of uricase
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS5599189A (en)	1979-01-22	1980-07-28	Mihama Hisaharu	Modified uricase free from antigenicity and its preparation
JPS55135590A (en)	1979-04-05	1980-10-22	Mihama Hisaharu	Modified asparaginase and uricase and their preparation
CH651308A5 (de)	1980-07-01	1985-09-13	Hoffmann La Roche	Interferone und deren herstellung.
JPS57192435A (en)	1981-05-20	1982-11-26	Toyobo Co Ltd	Modified polypeptide
DE3126759A1 (de)	1981-07-07	1983-01-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (en) *	1985-06-26	1990-12-27	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) *	1985-07-29	1989-07-11	Schering Corporation	Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de)	1986-03-10	1990-06-06	Akad Wissenschaften Ddr	Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) *	1986-04-23	1987-03-10	Mihama Hisaharu	修飾ウリカ−ゼ
JPH085506B2 (ja) *	1986-08-25	1996-01-24	日東製器株式会社	缶容器
DD279489A1 (de)	1986-12-11	1990-06-06	Leuna Werke Veb	Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) *	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en)	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
US5955336A (en) *	1988-08-17	1999-09-21	Toyo Boseki Kabushiki Kaisha	DNA sequence for uricase and manufacturing process of uricase
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en) *	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5382518A (en)	1989-07-13	1995-01-17	Sanofi	Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
NZ234453A (en) *	1989-07-13	1993-01-27	Sanofi Sa	Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5286637A (en)	1989-08-07	1994-02-15	Debiopharm, S.A.	Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja)	1989-11-01	1991-06-25	Sumitomo Pharmaceut Co Ltd	修飾ペプチドおよびその製造方法
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US5653974A (en)	1990-10-18	1997-08-05	Board Of Regents,The University Of Texas System	Preparation and characterization of liposomal formulations of tumor necrosis factor
WO1992016221A1 (en) *	1991-03-15	1992-10-01	Synergen, Inc.	Pegylation of polypeptides
EP0940154B1 (en)	1991-07-02	2007-04-18	Nektar Therapeutics	Device for delivering aerosolized medicaments
AU6240494A (en)	1993-02-16	1994-09-14	Enzon, Inc.	Ribosome inactivating protein compositions having reduced antigenicity
WO1994023740A1 (en) *	1993-04-22	1994-10-27	Celtrix Pharmaceuticals, Inc.	Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (en)	1993-06-21	1995-01-05	Enzon, Inc.	Site specific synthesis of conjugated peptides
IT1265101B1 (it) *	1993-07-23	1996-10-30	Erba Carlo Spa	Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5919455A (en)	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
KR960705579A (ko) *	1993-11-10	1996-11-08	에릭에스. 딕커	개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
CA2206852A1 (en) *	1994-12-07	1996-06-13	Novo Nordisk A/S	Polypeptide with reduced allergenicity
US5932462A (en) *	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) *	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
FR2733914B1 (fr) *	1995-05-11	1997-08-01	Sanofi Sa	Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en)	1995-06-07	1998-12-29	Chiron Corporation	Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja)	1995-12-05	1997-06-17	Asahi Chem Ind Co Ltd	ウリカーゼを生産する実質上純粋な微生物
ES2275300T3 (es)	1997-01-15	2007-06-01	Phoenix Pharmacologics, Inc.	Factor de necrosis tumoral modificado.
ATE274522T1 (de) *	1998-06-01	2004-09-15	Genentech Inc	Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie
IL141221A0 (en)	1998-08-06	2002-03-10	Univ Duke	Urate oxidase
CN1896231B (zh) *	1998-08-06	2012-09-05	山景药品公司	分离四聚体尿酸氧化酶的方法
US6783965B1 (en)	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
IL141220A0 (en)	1998-08-06	2002-03-10	Mountain View Pharmaceuticals	Conjugates of peg-urate oxidase and use thereof
US6425448B1 (en)	2001-01-30	2002-07-30	Cdx Gas, L.L.P.	Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) *	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
TWI538373B (zh)	2013-05-24	2016-06-11	中心微電子德累斯頓股份公司	切換式功率轉換器以及用於控制切換式功率轉換器的方法

2000
- 2000-02-10 US US09/501,730 patent/US6783965B1/en not_active Expired - Lifetime
2001
- 2001-02-06 TW TW090102540A patent/TWI322184B/zh not_active IP Right Cessation
- 2001-02-06 TW TW097145974A patent/TW200914617A/zh unknown
- 2001-02-07 DK DK10158016.5T patent/DK2196538T3/en active
- 2001-02-07 ES ES10180428.4T patent/ES2524153T3/es not_active Expired - Lifetime
- 2001-02-07 AU AU2001249975A patent/AU2001249975B2/en not_active Revoked
- 2001-02-07 DK DK10180428.4T patent/DK2305819T3/en active
- 2001-02-07 HU HU0204544A patent/HU227127B1/hu active Protection Beyond IP Right Term
- 2001-02-07 EP EP10180428.4A patent/EP2305819B1/en not_active Expired - Lifetime
- 2001-02-07 DK DK01923265.1T patent/DK1254237T3/da active
- 2001-02-07 CN CN2009101278530A patent/CN101735991B/zh not_active Expired - Lifetime
- 2001-02-07 KR KR1020077018682A patent/KR20070092329A/ko active Search and Examination
- 2001-02-07 BR BRPI0108386A patent/BRPI0108386B8/pt not_active Application Discontinuation
- 2001-02-07 EP EP01923265A patent/EP1254237B1/en not_active Expired - Lifetime
- 2001-02-07 NZ NZ520434A patent/NZ520434A/en not_active IP Right Cessation
- 2001-02-07 KR KR1020027010189A patent/KR100884724B1/ko active IP Right Grant
- 2001-02-07 EP EP10158016.5A patent/EP2196538B1/en not_active Expired - Lifetime
- 2001-02-07 KR KR1020087024272A patent/KR101054247B1/ko active IP Right Grant
- 2001-02-07 MX MXPA02007545A patent/MXPA02007545A/es active IP Right Grant
- 2001-02-07 AT AT01923265T patent/ATE463576T1/de active
- 2001-02-07 AU AU4997501A patent/AU4997501A/xx active Pending
- 2001-02-07 ES ES01923265T patent/ES2343105T3/es not_active Expired - Lifetime
- 2001-02-07 RU RU2002120486/13A patent/RU2281954C2/ru not_active IP Right Cessation
- 2001-02-07 PT PT101804284T patent/PT2305819E/pt unknown
- 2001-02-07 PL PL358539A patent/PL208064B1/pl unknown
- 2001-02-07 CN CNB018077501A patent/CN100491532C/zh not_active Expired - Lifetime
- 2001-02-07 WO PCT/US2001/040069 patent/WO2001059078A2/en active Application Filing
- 2001-02-07 CZ CZ2002-2982A patent/CZ304864B6/cs not_active IP Right Cessation
- 2001-02-07 CA CA2398679A patent/CA2398679C/en not_active Expired - Lifetime
- 2001-02-07 JP JP2001558218A patent/JP5165826B2/ja not_active Expired - Lifetime
- 2001-02-07 PT PT01923265T patent/PT1254237E/pt unknown
- 2001-02-07 RU RU2006107110/13A patent/RU2352354C2/ru active
- 2001-02-07 DE DE60141742T patent/DE60141742D1/de not_active Expired - Lifetime
- 2001-02-07 IL IL15106501A patent/IL151065A0/xx unknown
2002
- 2002-08-05 IL IL151065A patent/IL151065A/en active Protection Beyond IP Right Term
- 2002-09-09 ZA ZA200207206A patent/ZA200207206B/en unknown
2003
- 2003-12-11 HK HK03109064.9A patent/HK1056742A1/xx not_active IP Right Cessation
2007
- 2007-08-03 US US11/882,750 patent/US7927852B2/en not_active Expired - Fee Related
2008
- 2008-08-11 IL IL193365A patent/IL193365A/en active IP Right Grant
2009
- 2009-02-06 RU RU2009104003/10A patent/RU2557318C9/ru active
- 2009-09-02 AU AU2009212900A patent/AU2009212900B2/en not_active Expired
2010
- 2010-06-29 CY CY20101100597T patent/CY1110142T1/el unknown
- 2010-10-27 HK HK11109405.7A patent/HK1155203A1/zh not_active IP Right Cessation
- 2010-10-27 HK HK10110105.9A patent/HK1143989A1/zh not_active IP Right Cessation
- 2010-12-08 HK HK10111402.7A patent/HK1144701A1/xx not_active IP Right Cessation
2011
- 2011-04-12 JP JP2011088663A patent/JP5341945B2/ja not_active Expired - Lifetime
- 2011-04-13 US US13/085,793 patent/US8921064B2/en not_active Expired - Fee Related
2013
- 2013-07-03 BE BE2013C045C patent/BE2013C045I2/fr unknown
- 2013-07-03 LU LU92237C patent/LU92237I2/fr unknown
- 2013-07-04 FR FR13C0036C patent/FR13C0036I2/fr active Active
- 2013-07-04 CY CY2013028C patent/CY2013028I1/el unknown
2015
- 2015-02-09 CY CY20151100129T patent/CY1117264T1/el unknown

Also Published As

Publication number	Publication date
EP2305819A1 (en)	2011-04-06
TW200914617A (en)	2009-04-01
CN101735991A (zh)	2010-06-16
JP5165826B2 (ja)	2013-03-21
JP5341945B2 (ja)	2013-11-13
EP1254237A2 (en)	2002-11-06
DE60141742D1 (de)	2010-05-20
ATE463576T1 (de)	2010-04-15
US8921064B2 (en)	2014-12-30
CY1117264T1 (el)	2017-04-26
PL358539A1 (en)	2004-08-09
RU2557318C9 (ru)	2015-09-10
EP2196538B1 (en)	2014-10-01
HK1144701A1 (en)	2011-03-04
IL193365A0 (en)	2009-02-11
KR20020087934A (ko)	2002-11-23
RU2557318C2 (ru)	2015-07-20
ES2343105T8 (es)	2013-07-15
ES2524153T3 (es)	2014-12-04
CY1110142T1 (el)	2015-01-14
KR101054247B1 (ko)	2011-08-08
BR0108386C1 (pt)	2011-12-20
CY2013028I2 (el)	2015-11-04
CY2013028I1 (el)	2015-11-04
LU92237I2 (fr)	2013-09-03
PL208064B1 (pl)	2011-03-31
ZA200207206B (en)	2003-05-06
TWI322184B (en)	2010-03-21
KR20080098686A (ko)	2008-11-11
CA2398679C (en)	2015-11-17
HK1143989A1 (zh)	2011-01-21
HU227127B1 (en)	2010-07-28
EP2196538A1 (en)	2010-06-16
KR100884724B1 (ko)	2009-02-19
DK2305819T3 (en)	2015-01-05
CN101735991B (zh)	2013-09-11
PT2305819E (pt)	2015-06-01
DK1254237T3 (da)	2010-07-19
EP1254237B1 (en)	2010-04-07
HK1155203A1 (zh)	2012-05-11
CA2398679A1 (en)	2001-08-16
KR20070092329A (ko)	2007-09-12
BR0108386B1 (pt)	2017-10-31
AU2009212900A1 (en)	2009-10-01
ES2343105T3 (es)	2010-07-23
HUP0204544A2 (en)	2003-05-28
CN100491532C (zh)	2009-05-27
HK1056742A1 (en)	2004-02-27
MXPA02007545A (es)	2002-12-13
EP2305819B1 (en)	2014-11-12
CZ304864B6 (cs)	2014-12-17
IL151065A0 (en)	2003-04-10
RU2352354C2 (ru)	2009-04-20
US6783965B1 (en)	2004-08-31
BR0108386A (pt)	2002-10-29
WO2001059078A2 (en)	2001-08-16
CN1423699A (zh)	2003-06-11
NZ520434A (en)	2004-05-28
IL193365A (en)	2011-08-31
JP2011188861A (ja)	2011-09-29
US20110287466A1 (en)	2011-11-24
AU2009212900B2 (en)	2011-12-08
RU2009104003A (ru)	2010-08-20
HUP0204544A3 (en)	2007-05-02
BRPI0108386B8 (pt)	2021-05-25
CZ20022982A3 (cs)	2003-01-15
JP2003521937A (ja)	2003-07-22
WO2001059078A3 (en)	2002-03-07
US7927852B2 (en)	2011-04-19
RU2006107110A (ru)	2007-09-20
IL151065A (en)	2008-12-29
PT1254237E (pt)	2010-06-07
FR13C0036I1 (fr)	2013-08-09
US20080057048A1 (en)	2008-03-06
DK2196538T3 (en)	2015-01-05
AU2001249975B2 (en)	2006-06-08
RU2281954C2 (ru)	2006-08-20
FR13C0036I2 (fr)	2014-05-16
AU4997501A (en)	2001-08-20

Publication	Publication Date	Title
BE2013C045I2 (zh)	2020-06-24
KR940019312A (ko)	1994-09-14	폴리에틸렌 옥사이드로 개질된 단백질 및 폴리펩티드와 사이클로덱스트린의 동결 건조된 복합체
HK1076115A1 (en)	2006-01-06	Polyol-ifn-beta conjugates
WO2002002143A3 (en)	2002-07-18	Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
CA2122717A1 (en)	1993-05-13	Hemoglobins as drug delivery agents
PT1100542E (pt)	2005-11-30	Conjugado de peg-uricase oxidase e seu uso
CA2064689A1 (en)	1991-02-02	Stabilized protein or peptide conjugates
DE60006100D1 (de)	2003-11-27	Lang wirkende insulinotrope peptide
NZ509595A (en)	2004-02-27	Peg-urate oxidase conjugates and use thereof
MX9604402A (es)	1997-07-31	Proteina similar a albumina serica humana.
NO983054D0 (no)	1998-07-01	Virale rekombinante pseudopartikler og anvendelse som vaksiner og som anti-tumormiddel
DE60223232D1 (de)	2007-12-13	Mucinpeptid mit immunstärkenden eigenschaften
TW200619386A (en)	2006-06-16	Polyol-IFN-beta conjugates
Yuecel et al.	1998	Increased susceptibility to oxidative stress in lens tissues of sulfur dioxide exposed rats